米国企業
Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.HEPA

時価総額

$293.9万

PER

	2014年 6月30日	2015年 6月30日	2016年 6月30日	2017年 6月30日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日
Cash	2	5	7	13	3	14	41	91	51
Prepaid expenses	164,421	681,249	491,045	210,174	135,591	465,693	2	6	5
Total current assets	2	5	8	13	3	14	43	97	56
Property and equipment, net	14,526	81,441	80,848	67,564	32,434	57,166	108,440	152,772	81,620
Right-of-use assets	-	-	-	-	-	797,913	556,492	0	0
In-process research and development	-	-	3	3	3	3	3	3	3
Goodwill	-	-	2	2	2	2	2	2	-
Other assets	4,200	51,344	69,955	63,182	127,794	127,939	285,098	583,326	426,174
Total assets	2	5	13	18	8	20	49	104	60
Accounts payable	243,896	1	4	2	748,428	491,557	4	2	3
Accrued expenses	207,915	456,722	820,894	1	661,421	493,636	659,572	3	5
Operating Lease, Liability, Current	-	-	-	-	-	266,696	279,826	0	0
Short-term portion of contingent consideration	-	-	-	-	-	-	-	3	0
Total current liabilities	458,739	2	5	3	3	1	5	8	8
Contingent consideration, non-current	-	-	3	3	3	2	3	2	2
Deferred tax liability	-	-	-	-	-	18,752	409,022	409,022	409,022
Operating Lease, Liability, Noncurrent	-	-	-	-	-	540,751	0	0	-
Total liabilities	5	2	12	9	6	4	8	11	10
Series A	-	13	13	1	855,808	855,808	855,808	855,808	855,808
Series C	-	-	-	-	930,311	861,033	856,320	845,320	840,320
Common Stock, Value, Issued	1,848	2,228	3,224	7,571	1,661	375	3,203	7,623	7,623
Additional paid-in capital	2	17	32	68	77	98	143	225	224
Accumulated other comprehensive loss	-	-	-	-	-	-	-	-	-90,168
Accumulated deficit	-5,421,337	-27,613,857	-44,612,495	-59,503,545	-76,463,932	-83,185,630	-104	-133	-176
Series A	-	13	13	1	855,808	855,808	855,808	855,808	855,808
Series C	-	-	-	-	930,311	861,033	856,320	845,320	840,320
Total stockholders equity	-2,933,180	3	1	9	2	16	41	93	50
Total liabilities and stockholders’ equity	2	5	13	18	8	20	49	104	60